Highest-materiality recent filing
Brady Q3 adj. EPS record $1.50, raises FY guidance, agrees to buy Honeywell PSS
Record adj. EPS $1.50 (+23% YoY); GAAP EPS $1.21 (+11%); sales $435M (+13.8%).
Two directors resign from Brady Corp board effective May 8, 2026
Deidre E. Cusack and Anne De Greef-Safft resigned from Brady's Board of Directors.
Brady Corp to acquire Honeywell's PSS business for $1.4B cash, ~8x EBITDA
Purchase price $1.4B, ~8x 2025 EBITDA; PSS generated $1.1B sales in 2025 with 3,000 employees.
Director Christopher M. Hix to leave Brady Board effective March 31, 2026
Director Christopher M. Hix notified resignation from board effective March 31, 2026.
Brady Q2 FY2026 EPS $1.01 (+21.7% YoY); guides adjusted EPS $4.95-$5.15
Sales $384.1M (+7.7% YoY) with organic growth of 1.6%, acquisitions 2.3%, FX 3.8%.
Brady Corp elects board, declares $0.245 quarterly dividend payable Jan 30, 2026
All 11 director nominees unanimously elected at the December 3, 2025 annual meeting.
Brady Q1 sales up 7.5% to $405.3M; adj. EPS $1.21; raises low end of FY26 guidance
Organic sales grew 2.8%; acquisitions added 3.2%; FX added 1.5%.
Brady Corp enters new change-of-control agreement with General Counsel Andrew Gorman
Agreement provides 2x base salary plus 2x target bonus upon qualifying termination within 24 months of a change of control.
Brady Q4 adj EPS record $1.26; FY2026 guide $4.85-$5.15 adj; dividend raised for 40th year
Q4 sales $397.3M (+15.7% YoY), organic +2.4%; GAAP EPS $1.04, adjusted EPS $1.26 (record, +5.9% YoY).
Brady Q3 fiscal 2025 adjusted EPS record $1.22; tightens full-year guidance
Sales $382.6M, +11.4% YoY; organic +1.6%, acquisitions +10.5%, FX -0.7%.
Brady Corp elects Anne De Greef-Safft to Board of Directors effective Feb 25, 2025
Anne De Greef-Safft appointed to Brady's Board and Audit Committee, effective February 25, 2025.
Brady Corp Q2 adjusted EPS $1.00 beats $0.93 YoY; raises low end of FY2025 guidance
Sales $356.7M (+10.6% YoY); organic growth +2.6%; acquisitions +10.2%; foreign exchange -2.2%.
Brady Corp declares $0.24 quarterly dividend; shareholders elect 10 directors
Quarterly dividend of $0.24 per share declared, payable Jan 31, 2025 to holders of record Jan 10, 2025.
Brady Corp Q1 sales $377.1M (+13.6%), adj. EPS $1.12 (+12% YoY); FY guidance reaffirmed
Sales organic growth 3.6%; acquisitions (incl. Gravotech) contributed 9.9%; net cash $29.0M after $140.6M in deal spend.
Brady Corp amends credit agreement, replacing CDOR with Term CORRA for CAD borrowings
Third Amendment to $300M credit agreement dated Oct 10, 2024; changes Canadian Dollar benchmark from CDOR to Adjusted Term CORRA.
Brady Corp elects Deidre Cusack to Board; former Dematic EVP joins Technology Committee
Deidre Cusack elected to Brady's Board effective September 4, 2024; appointed to Technology Committee.
Q4 diluted EPS $1.15 (record), +15% YoY; adjusted EPS $1.19, +14.4%; net income $55.5M vs $49.4M.
Brady completes acquisition of Gravotech for EUR 120M (~USD 130M)
Acquisition of Gravotech closed Aug 1, 2024; enterprise value EUR 120M (~USD 130M).
Brady Corp acquires Gravotech Holding for EUR 120M (~USD 130M)
100% share capital and voting rights acquired via cash purchase price of EUR 120M (~USD 130M), subject to working capital adjustment.
Brady appoints Thomas DeBruine as COO effective June 3, 2024
DeBruine promoted from VP Global Operations to COO, reporting to CEO Russell Shaller.
Brady Corp elects Christopher Hix to Board of Directors effective May 24, 2024
Hix appointed to Audit Committee and Finance Committee effective May 24, 2024.
Brady posts record Q3 EPS of $1.05; raises FY2024 guidance
Q3 GAAP EPS $1.05 (record), +9.4% YoY; adjusted EPS $1.09, +14.7% YoY.
Brady Corp agrees to acquire Gravotech Holding for €123M (~$133M)
Purchase price €123M (~$133M); funded through cash on hand and existing credit facility.
Brady Q2 EPS up 18.4% to $0.90; raises low end of FY2024 guidance
GAAP diluted EPS $0.90 (up 18.4% YoY); adjusted EPS $0.93 (up 14.8% YoY).
Brady Q1 EPS $0.97 beats prior year; organic sales +2.7%; guidance reaffirmed
Sales $332.0M (+2.9% YoY); organic +2.7% with Americas & Asia +3.3% and Europe & Australia +1.4%
On May 6, 2026, Deidre E. Cusack and Anne De Greef-Safft notified Brady Corporation (the "Company") of their respective resignations from the Company’s Board of Directors effective May 8, 2026.
On May 6, 2026, Deidre E. Cusack and Anne De Greef-Safft notified Brady Corporation (the "Company") of their respective resignations from the Company’s Board of Directors effective May 8, 2026.
On February 25, 2025, the Board of Directors of Brady Corporation (the “Company”) elected Anne De Greef-Safft to join the Board of Directors, effective immediately.
On September 4, 2024, the Board of Directors of the Company elected Deidre Cusack to join the Board of Directors, effective immediately.
appointed Thomas DeBruine to serve as Chief Operating Officer, effective June 3, 2024
On May 20, 2024, the Board of Directors of Brady Corporation (the “Company”) elected Christopher Hix to join the Board of Directors, effective May 24, 2024.
Max materiality 0.90 · Median 0.65 · Most common event earnings